Past Events

Upcoming Events | Past Events
Urogen Pharma at Jefferies 2018 Global Healthcare Conference
Tuesday, June 5, 2018 11:00 a.m. ET

Urogen Pharma at The 113th American Urological Association’s (AUA) Annual Meeting
Monday, May 21, 2018 10:40 a.m. PT
Supporting Materials
Download Event Supporting Material UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

Urogen Pharma Q1 2018 Earnings Conference Call
Tuesday, May 15, 2018 8:30 a.m. ET

UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
Wednesday, April 25, 2018 9:15 a.m. ET

Urogen Pharma at Oppenheimer 28th Annual Healthcare
Wednesday, March 21, 2018 9:45 a.m. ET

Q4 2017 Urogen Pharma Earnings Conference Call
Thursday, March 15, 2018 8:30 a.m. ET

Presentation Cancelled due to Weather: Urogen Pharma at Cowen & Company 38th Annual Health Care Conference
Tuesday, March 13, 2018 8:00 a.m. ET
Description

Presentation cancelled due to weather


Urogen Pharma 36th Annual J.P. Morgan Healthcare Conference Q&A Session
Thursday, January 11, 2018 9:30 a.m. PT

Urogen Pharma at 36th Annual J.P. Morgan Healthcare Conference
Thursday, January 11, 2018 9:00 a.m. PT

Society of Urologic Oncology (SUO) Annual Meeting
Wednesday, November 29, 2017 1:30 p.m. ET
DescriptionSeth Lerner, M.D., principal investigator for the Company’s ongoing pivotal Phase 3 OLYMPUS trial of MitoGel™ for the treatment of low-grade upper tract urothelial carcinoma (UTUC), will conduct an oral presentation during a plenary session at the 18th annual meeting of the Society of Urologic Oncology (SUO), taking place November 29-December 1, 2017, in Washington, D.C. Dr. Lerner will provide an overview of the design of the Phase 3 OLYMPUS trial, including metrics of success and basic patient inclusion and exclusion criteria. In addition, Dr. Lerner will present key data highlights from the Company’s recently completed compassionate use program with MitoGel™ for the treatment of UTUC. Topline data from the Phase 3 OLYMPUS trial are expected to be available in the second quarter of 2018. Details of the presentation are as follows: Title: Thermo Reversible Hydrogel Based Delivery of Mitomycin C (MitoGel) for Treatment of Upper Tract Urothelial Carcinoma Presenter: Seth Paul Lerner, M.D., FACS, Professor of Urology at Baylor College of Medicine Time: Thursday, November 30, 2017, 1:30 p.m. EST Location: Renaissance Washington DC Downtown Hotel, Washington, D.C.

Q3 2017 Urogen Pharma Earnings Conference Call
Tuesday, November 14, 2017 8:30 a.m. ET

Urogen Pharma at the Rodman & Renshaw 19th Annual Global Investment Conference
Monday, September 11, 2017 2:35 p.m. ET

Ringing the Nasdaq Stock Market Opening Bell
Thursday, June 8, 2017 9:30 a.m. ET

Urogen Pharma at Jefferies 2017 Global Healthcare Conference
Tuesday, June 6, 2017 1:30 p.m. ET